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Objectives: Despite relevant treatments, only 29% of type 2 diabetes (T2DM) 
patients in Greece achieve their pre-defined glycemic targets. When treatment 
with metformin (MF) fails to control T2DM patients, add-on therapies are needed. 
Sitagliptin is indicated as second-line therapy in Greece, after treatment with MF 
has failed and is a valid option in the proposed national therapeutic protocols. 
The present study aimed to assess the cost-effectiveness of adding Sitagliptin to 
MF vs adding sulphonylurea (SU) to MF for the treatment of T2DM patients with 
inadequate glycemic control. MethOds: A published individual-level simulation 
model was developed to simulate the lifetime medical cost, diabetic complications, 
drug-related adverse events, life expectancy and quality adjusted life years (QALYs) 
associated with Sitagliptin add-on therapy versus SU add-on therapy. The model is 
developed based upon the UKPDS 68 risk equations to project long-term complica-
tions and mortalities. Efficacy and safety profiles of drugs were obtained from a 
head-to-head trial. Costs (€ 2014 prices) and effects were discounted at 3.5% annu-
ally. Greek data retrieved by an expert input forum of specialists. Sensitivity analyses 
performed on 17 parameters. Analysis based on Greek payer perspective. Results: 
Sitagliptin strategy is projected to cost 359 EUR more than SU strategy per patient 
over lifetime. Sitagliptin showed reductions in diabetes-related complications and 
adverse events. The incremental QALY for Sitagliptin strategy is 0.042, primarily 
driven by the improved outcomes associated with hypoglycemia, body weight 
change, and MI. The incremental cost effectiveness ratio (ICER) is 8,582 € /QALY 
gained. Sensitivity analysis conducted varied multiple parameters. ICER ranges 
from 4,873 to 12,173 € /QALY gained. The results are robust and never exceeded the 
30,000€ /QALY threshold. cOnclusiOns: Sitagliptin add-on strategy could be cost-
effective, compared to SU, for the Greek healthcare setting. Furthermore, it remains 
cost-effective in all types of sensitivity analysis.
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Objectives: to assess the cost effectiveness of saxagliptin (SAXA) vs sitagliptin 
(SITA) or vildagliptin (VILDA) as add-on therapy to metformin (MET) in patients with 
type 2 diabetes mellitus (T2DM) and inadequate glycaemic control on metformin 
alone. MethOds: the Cardiff Diabetes Model was adapted to the Russian health-
care setting. We modeling events, efficacy, total costs for managing patients with 
T2DM: 1-st line – monotherapy metformin alone, 2-nd line (target groups) – SAXA or 
SITA or VILDA plus metformin, 3-nd line – insulin rescue therapy. The model simu-
lated the disease progression and treatment effects for 40 years (8-26-6 years for 
1-2-3 lines respectively). The effectiveness measure was quality-adjusted life years 
(QALYs) gained per patient. Results: in case short-time efficacy (decrease HBA1c 
-1%) cost-effectiveness ratio (CER) for SAXA+MET was the lowest: $835 per QALY. 
When compared with SITA+MET for the long-term efficacy (40 years), SAXA+MET 
was the dominant strategy, i.e. less costly (-$505) and more effective (+0.16 QALY). 
When compared to VILDA+MET, SAXA+MET was more costly (+$364), but more 
effective (+0.14 QALY). The incremental cost-effectiveness ratio (ICER) per responder 
for SAXA+MET vs VILDA+MET was estimated at $2,566 per QALY gained and would 
be cost effective at the willingness-to-pay (WTP) threshold $36,373/QALY for 
Russia in 2014. If we used combined medicines: Kombiglyce (SAXA+MET), Janumet 
(SITA+MET) and Galvus Met (VILDA+MET), then Kombiglyce interventions were also 
more efficacious than Janumet and Galvus Met, but were associated with increased 
total costs. The ICERs per responder for Kombiglyce were estimated at $3,216/QALY 
(vs Janumet), $3,269/QALY (vs Galvus Met) and would be cost effective at the WTP 
threshold $36,373/QALY for Russia in 2014. cOnclusiOns: at a willingness-to-pay 
threshold of $36,373/QALY SAXA+MET and Kombiglyce is likely to be a cost-effective 
option for the treatment of T2DM in adult patients in Russia.
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Objectives: Establish incremental cost-effectiveness ratio (ICER) in cost per 
additional patient with glycemic control for all the oral antidiabetic medications 
available in Colombia, as a second-line treatment for adult patients with type 2 
diabetes (DM2), who do not reach therapeutic targets with metformin and are 
not yet considered candidates for insulin therapy. MethOds: Oral antidiabetic 
medications were divided into drug classes: sulfonylureas (divided between glib-
enclamide, other sulphonylureas), thiazolidinediones, GLP-1 receptor agonists, and 
DPP4 inhibitors. A systematic review of the literature was done to obtain transition 
probabilities in a Markov model (monthly cycles, time horizon one year) designed 
to represent the Colombian health system perspective. The main outcome consid-
ered was glycemic control, but data on adherence and adverse events were also 
collected. Costs (in 2014 Colombian pesos; 1 euro = COP 2,660) were estimated 
from base cases obtained from multidisciplinary expert panel meetings, with 
local costs applied from national tariff manuals and official drug price registries. 
Sensitivity analyses were performed. Results: Annual treatment costs ranged 
from € 116 for glibenclamide, and € 98 for other sulphonylureas, to € 12,205 for 
GLP-1 receptor agonists. Number of patients with glycemic control (per 1000) were 
glibenclamide 145, sulphonylureas 265, thiazolidinediones 472, GLP-1 receptor 
agonists 326, and DPP4 inhibitors 417: Compared against other sulfonylureas, 
glibenclamide was dominated, while ICERs per additional patient with glycemic 
control per year would be € 516 for DPP-4 inhibitors, € 712 for thiazolidinediones 
and € 66,790 for GLP-1 receptor agonists. Critical variables in the sensitivity analy-
ses were drug costs (particularly for GLP-1 receptor agonists), but also patient 
policy making. MethOds: A published decision-analysis tool (the GeDiForCETM) 
was employed to assess cost-effectiveness of GDM screening by comparing costs 
and averted disability-adjusted life years (DALYs) with no GDM screening. As mod-
eling inputs, costs for GDM screening and antenatal care, incidence and cost of 
GDM perinatal adverse effects (PAE) were based on an investigation on 6 tertiary 
hospitals from different cities in China as part of this analysis. Cost for postpartum 
care was calculated based on literature and adjusted for China. PAE-DALYs, life-
time cost for postpartum T2DM, and effectiveness of interventions were collected 
from literature. Annual discount rate was 3.0%. One-way sensitivity analyses were 
conducted on some key indicators. Results: The total costs of GDM screening, 
intervention and life-time treatment per 1000 pregnant women were $7,092,398 in 
GDM screening group, saving $1,329,671 comparing with no screening. 277.4 DALYs 
were averted in screening group, which was mainly brought out by GDM postpartum 
care for T2DM prevention. Sensitivity analyses demonstrated robustness of the 
results. cOnclusiOns: GDM screening and interventions are cost-saving in an 
urban Chinese setting by IADPSG standards. As DALYs averted mainly comes from 
T2DM prevention, China should pay more attention to providing postpartum care 
for GDM women in the future.
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Objectives: Improving glycaemic control is the primary goal of T2DM manage-
ment and can help to reduce the risk of micro- and macrovascular complications. 
Guidelines from the American Diabetes Association and European Association for 
the Study of Diabetes recommend lowering HbA1c to levels < 7.0% for most patients. 
This analysis compared the cost of reaching this target (HbA1c < 7.0%) using cana-
gliflozin versus dapagliflozin, two compounds that inhibit sodium glucose co-trans-
porter 2 (SGLT2), in dual therapy as add-on to metformin from the payer perspective 
in the UAE. MethOds: A Bayesian network meta-analysis (NMA) was conducted 
to compare the efficacy of canagliflozin 100 and 300 mg versus dapagliflozin 10 
mg in terms of the percentage of patients that achieved the HbA1c goal of < 7.0% 
at 26 weeks. Based on the NMA results and the acquisition cost of dapagliflozin 
in the UAE ($1.77 per day), we calculated what the daily acquisition cost of each 
dose of canagliflozin would be if the costs of a patient reaching the target with 
canagliflozin 100 and 300 mg were equalized to the cost of reaching the target with 
dapagliflozin 10 mg. Results: In dual therapy as add-on to metformin, patients 
using canagliflozin 100 and 300 mg were more likely to achieve HbA1c < 7.0% com-
pared to those using dapagliflozin 10 mg, with odds ratios of 1.3 (Pr= 82%) and 1.7 
(Pr= 96%), respectively. The costs of canagliflozin 100 and 300 mg that equalized the 
cost of reaching HbA1c < 7.0% with dapagliflozin 10 mg were $2.11 and $2.45 per 
day, respectively. cOnclusiOns: These results suggest that adding canagliflozin 
100 or 300 mg instead of dapagliflozin 10 mg in patients inadequately controlled 
on metformin would result in a more efficient use of resources with costs per day 
up to these break-even levels.
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Objectives: This study was designed to assess the cost-effectiveness of vildagliptin 
versus glimepiride as add-on to metformin in the management of type 2 diabetes 
mellitus (T2DM) patients in the Greek healthcare setting. MethOds: A cost-effec-
tiveness model was designed, using MS Excel, to compare two treatment strategies. 
Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in 
second-line, and metformin + basal insulin and metformin + basal + rapid insulin 
in subsequent lines. Strategy 2 differed from strategy 1 only in second-line, where 
metformin was administered with glimepiride. Clinical data and utilities were taken 
from the published literature. Only direct medical costs were included in the analy-
sis (cost base year 2014), and consisted of drug, side-effect and comorbidity costs 
(taken from local officially published sources and the literature). The perspective 
adopted was that of the Social Insurance Fund. The time horizon was lifetime, and 
costs and outcomes were discounted at 3.5%. Results: Adding vildagliptin to met-
formin increased drug costs compared with adding glimepiride to metformin (€ 2,853 
vs. € 2,427, respectively). However, this increase was completely offset by a decrease 
in the costs of associated comorbidities (€ 4,393 vs. € 4,539) and side-effects (€ 3,015 vs. 
€ 3,510), resulting in a lower total cost of € 214.6 in strategy 1 compared with strategy 
2. Comorbidities were the largest cost component in both strategies, accounting for 
42.8% and 43.3% in strategies 1 and 2, respectively. Strategy 1 was also associated 
with increased life-years (LYs, 0.11) and quality-adjusted life-years (QALYs, 0.11) 
compared with strategy 2. Strategy 1 is therefore dominant, as it is associated with 
both lower overall costs and increased effectiveness. cOnclusiOns: Vildagliptin as 
add-on treatment to metformin in the management of T2DM in Greece appears to 
be dominant vs. glimepiride in terms of both cost per LY and cost per QALY gained.
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cases, 2,376 hospitalizations, and 236 deaths. Associated influenza costs avoided 
were estimated at more than TRY 8.3 million, while the cost of vaccination would 
be more than TRY 8.4 million. The incremental cost-effectiveness ratio (ICER) was 
estimated at TRY 64/QALY, which is below the GDP per capita and very cost-effective. 
Factors most influencing the ICER were excess hospitalisation rate, inpatient cost, 
vaccine effectiveness against hospitalization, and attack rate. In addition, increas-
ing vaccination coverage rate to above 20% was also estimated to be very cost-
effective. cOnclusiOns: Increasing the influenza vaccination coverage rate for 
adults with type 2 diabetes in Turkey to 20% or higher would be very cost-effective. 
To reduce influenza burden in diabetic patients, an integrated care approach is 
needed and all stakeholders need to cooperate to increase the vaccination coverage 
rates to WHO recommended levels.
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Objectives: Insulin analogues offer certain advantages over regular human insu-
lin. Our objective was to establish the incremental cost-effectiveness ratio (ICER) 
of insulin analogues compared with human insulin, with multiple daily injections 
(MID) in adult patients with type 1 diabetes mellitus (DM1) in Colombia. MethOds: 
We designed a Markov model of annual cycles, time horizon of up to 55 years, 
from a third-party payer perspective (only direct medical costs for the Colombian 
healthcare system) and applying discount rate of 3.5% both for costs and outcomes. 
Quality-adjusted life years (QALYs), taken from published literature, were used as 
a measure of effectiveness with a threshold of three times the per capita gross 
domestic product (GDP), approximately € 17,550. The comparison between analog 
and human insulin was performed separately for short and long term. The costs 
were in Colombian pesos (1 € = COP 2.660), and were built through base cases 
designed by interdisciplinary expert panels, with drug prices and costs of interven-
tions or adverse events were estimated using official tariff manuals and databases. 
Univariate and probabilistic sensitivity analysis were performed. Results: Despite 
certain clinical advantages, insulin analogues gain, on average, very few QALYs (from 
0.02 to 0.1 depending on scenarios). With this result, the average ICER for short-term 
insulins would be € 78,900; while long duration insulin analogues have an ICER of 
€ 94,550. Results were highly sensitive to price of medication, as well as to disutil-
ity or costs of hypoglycemic events. cOnclusiOns: Given the assumptions and 
limitations of our model, insulin analogues would not be considered cost-effective 
within the Colombian healthcare system compared with multiple daily injections 
for adult patients with DM1.
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Objectives: The objective is to describe disease progression and treatment pat-
terns of acromegaly in patients with inadequate biochemical control, assess how 
biochemical control will impact disease progression and treatment pathways and 
estimate the economic efficiency of pasireotide long-acting (PASI) in a treatment of 
acromegaly in Finland. PASI is compared to pegvisomant + somatostatin analoque 
(PEG+SSA) in patients with inadequately controlled acromegaly. MethOds: A 
5-state Markov model describing the disease progression and management of 
acromegaly was constructed. The model enables an assessment of how biochemi-
cal control associated with PASI is translated into Quality Adjusted Life Years 
(QALYs), costs and subsequently incremental cost-effectiveness ratio. Transition 
probabilities were determined by clinical trial data (study 2402) in 6 month cycles. 
Achievement of control has an impact on quality of life, mortality risk and preva-
lence of comorbidities, whereas achievement of tumor reduction will have an 
impact on quality of life. Utilities for each health state were derived from the 2402 
trial and the literature. The annual visit, monitoring and comorbidity costs were 
estimated by treatment response and were based on patient level data (n= 66) 
from Auria biobank. The analysis was undertaken from health care payer perspec-
tive using 30-years time horizon. Results: PASI dominated PEG+SSA treatment 
strategy. PASI was associated with more than 100,000€ lower costs compared to 
PEG+SSA. This is primarily driven by the lower pharmaceutical cost.PASI patients 
were on average 0.19 more years in biochemical control compared with PEG+SSA 
and was associated with QALY gain of 0.02. The difference in QALYs result from 
the tumor reduction achieved with PASI as well as the drop-out rate due to liver 
toxicities occurring in PEG+SSA strategy. cOnclusiOns: PASI provides a valu-
able addition to the treatment options for patients with acromegaly and can 
achieve mortality as well as morbidity improvements in a cost-effective way in 
Finland.
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Objectives: Evaluate the cost analysis of fix dose combination of dapagliflozin 
plus metformin (DAPA+MET) compared with glipizide plus metformin (SU+MET), 
in the treatment of type 2 diabetes mellitus during one year. MethOds: A ran-
adherence to medication (with insuficient local information). cOnclusiOns: 
Sulfonylureas, other than glibenclamide, DPP-4 inhibitors and thiazolidinediones 
are cost-effective alternatives as second-line treatment for DM2 patients that 
require oral antidiabetics in Colombia. Patient adherence requires further local 
research.
PDB66
coSt-EffEctivEnESS analySiS of ExEnatiDE twicE Daily (BiD) vErSuS 
inSulin glarginE oncE Daily (QD) aS aDD-on thEraPy in chinESE 
PatiEntS with tyPE 2 DiaBEtES mEllituS inaDEQuatEly controllED By 
oral thEraPiES
Deng J1, Gu S2, Shao H3, Dong H4, Zhao Y5, Shi L3
1Johns Hopkins Bloomberg School of Public Health, Baltimore, LA, USA, 2Zhejiang University 
School of Medicine, Hangzhou, China, 3Tulane University, New Orleans, LA, USA, 4Zhejiang 
Univerisity, Hangzhou, China, 5Xavier University of Louisiana, New Orleans, LA, USA
Objectives: To estimate cost-effectiveness of exenatide twice daily (BID) versus 
insulin glargine once daily (QD) as add-on therapy in Chinese type 2 diabetes 
patients not well controlled by oral anti-diabetic (OAD) agents. MethOds: The 
Cardiff model was populated with the data synthesized from three head-to-head 
randomized clinical trials up to 30 weeks in China comparing exenatide BID vs 
insulin glargine as add-on therapies to oral therapies in the Chinese population. 
The Cardiff model generated outputs including macrovascular and microvascular 
complications, diabetes-specific mortality, costs and quality-adjusted life years 
(QALYs). Cost and QALYs were estimated with time horizon of 40 years at a dis-
count rate of 3% from the societal perspective Results: Compared with insulin 
glargine plus OAD treatments, patients on exenatide BID plus OAD gained 1.88 
QALYs, at an incremental cost saving of Chinese Renminbi (RMB) 114,593 (i.e., cost 
saving of RMB 61078/QALY). The cost-effectiveness results were robust to vari-
ous sensitivity analyses including probabilistic sensitivity analysis. The variables 
with the most impact on incremental cost-effectiveness ratio included HbA1c 
level at baseline, health utilities decrement and BMI at baseline. cOnclusiOns: 
Compared with Insulin glargine QD, exenatide BID as add-on therapy to OAD is a 
cost-effective treatment in the Chinese patients inadequately controlled by OAD 
treatments.
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Objectives: Diabetes mellitus type 2 is a chronic disease, with many issues both 
in terms of pathophysiology and therapy; its incidence is steadily increasing, in 
line with the increase of the aging population. For this reason, diabetes could 
be considered an emergency also for its economic burden. MethOds: We per-
formed a cost minimization analysis to evaluate the impact of different treat-
ments on patients with type 2 diabetes, kidney failure, on dialysis, from moderate 
to severe stage, who failed monotherapy with metformin. We considered direct 
and indirect costs: the resources consumed in providing facilities and those 
used to counter the negative effects of the different treatments, and produc-
tion losses of patients. Results: We compared the following hypoglycemic mol-
ecules: Pioglitazone (15, 30), Repaglinide (0.5, 1, 2), Vildagliptin50 and Linagliptin5. 
Regarding insulin therapy, we consider the following classifications: Insulins 
human, Basal analogs and Fast analogs. An analysis of the direct medical costs 
of treatment and loss of production shows an average annual cost per patient 
treated with insulin between € 1,005.63 - € 1,098.34, with differentials cost vs. other 
hypoglycemic strategies between € 174 and € 203. The cost for the management 
of hypoglycemia is greatest with the insulin treatment but with a limited impact 
on the total cost of health care and treatment. The loss of working days due to 
treatment and to hypoglycemic episodes have a considerable impact (71% of the 
total cost). The total cost related to a treatment with of Vildagliptin is in line with 
that of other strategies. Furthermore Vildagliptin has a lower economic impact, 
if taken into account indirect costs. cOnclusiOns: The cost analysis of therapy 
applied to diabetes demonstrates that the use of Vildagliptin represents a choice, 
that is economically favorable if we consider the whole diabetic population costs, 
including renal insufficiency patients.
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Objectives: Influenza triggers high risk of complications in patients with diabetes. 
Influenza vaccination is safe and effective in diabetic patients. In Turkey, the preva-
lence of diabetes is high but the influenza vaccination coverage rate is low, 9.1% in 
2014, despite vaccination being recommended and reimbursed in this population. 
This study therefore, evaluated the cost-effectiveness of increasing the influenza 
vaccination coverage rate of adults aged ≥ 18 years with type 2 diabetes in Turkey 
to 20%. MethOds: A decision-analytic model was adapted to Turkey using data 
derived from published sources. Based on the literature, patients with diabetes 
have a 6-fold increase in influenza-related hospitalization and 3-fold increase in 
influenza-related death compared to healthy individuals. Direct medical costs and 
indirect costs due to productivity loss were included in the societal perspective. 
Costs were calculated in Turkish Lira (TRY) (0.43 per US dollar in 2014). A one-year 
time horizon was set to reflect influenza seasonality. Results: Increasing the 
influenza vaccination coverage rate to 20% is predicted to avert 19,777 influenza 
